Newton, Massachusetts, USA, November 17, 2026
Karyopharm Therapeutics Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) in combination with ruxolitinib for the treatment of patients with myelofibrosis. The regulatory milestone represents an important step toward expanding the therapeutic applications of selinexor beyond its existing multiple myeloma indications. The application is primarily supported by findings from the pivotal Phase III SENTRY clinical trial, which evaluated the combination in patients with previously untreated myelofibrosis using JAK inhibitor therapy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2027, by which the agency is expected to complete its review and communicate its regulatory decision. If approved, selinexor combined with ruxolitinib could become the first FDA-approved combination therapy for patients with myelofibrosis, potentially introducing a new treatment approach for this rare and serious blood cancer. The submission highlights Karyopharm’s continued efforts to develop targeted therapies for patients with significant unmet medical needs in hematological oncology.
FDA Accepts XPOVIO Combination Application for Review
The FDA’s acceptance of the sNDA marks a significant regulatory development for Karyopharm’s investigation of selinexor in myelofibrosis. The application seeks approval of XPOVIO (selinexor) combined with ruxolitinib, a Janus kinase (JAK) inhibitor commonly used in the management of myelofibrosis. The combination is designed to target different biological mechanisms associated with disease progression and symptom burden. Ruxolitinib inhibits JAK1 and JAK2 signalling, helping manage abnormal blood cell production and disease-related symptoms, while selinexor works through a different mechanism by selectively inhibiting exportin 1 (XPO1), a nuclear export protein involved in regulating the movement of important cellular proteins. By combining these mechanisms, researchers aim to improve treatment outcomes compared with JAK inhibitor therapy alone. According to Karyopharm, the FDA submission is primarily based on the results of the Phase III SENTRY trial. The clinical findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the peer-reviewed Journal of Clinical Oncology. Additional results were presented at the 2026 European Hematology Association Congress, where the presentation was recognized among the meeting’s six best abstracts. The assigned PDUFA date of June 28, 2027, establishes the anticipated timeline for the FDA’s regulatory review.
Phase III SENTRY Trial Evaluates Combination Treatment
The pivotal Phase III SENTRY trial (XPORT-MF-034; NCT04562389) evaluated the efficacy and safety of selinexor combined with ruxolitinib compared with placebo plus ruxolitinib in patients with previously untreated myelofibrosis. The randomized study enrolled 353 patients with platelet counts greater than 100 × 10⁹/L who had not previously received JAK inhibitor treatment. Participants were randomized in a 2:1 ratio to receive either selinexor or placebo alongside ruxolitinib. Patients in the experimental treatment group received selinexor 60 mg once weekly in combination with ruxolitinib. The study included two co-primary endpoints designed to evaluate improvements in disease-related outcomes. The first endpoint measured the proportion of patients achieving at least a 35% reduction in spleen volume from baseline at Week 24, known as spleen volume reduction 35% (SVR35). The second assessed the average change in absolute total symptom score (Abs-TSS) over 24 weeks compared with baseline. These measurements are clinically important because myelofibrosis frequently causes an enlarged spleen and debilitating symptoms that can significantly affect patients’ daily lives. The trial’s findings provide the principal clinical evidence supporting the regulatory submission. However, the FDA’s acceptance of the application does not mean the combination has received marketing authorization, and the final regulatory decision will depend on the agency’s assessment of the submitted evidence.
Selinexor Development Expands Myelofibrosis Treatment Opportunities
Myelofibrosis is a rare, progressive blood cancer characterized by bone marrow scarring, which interferes with the body’s ability to produce healthy blood cells. Patients may experience anemia, fatigue, weakness, an enlarged spleen, abdominal discomfort, night sweats and bone pain. Karyopharm estimates that approximately 20,000 people in the United States and 19,000 in the European Union are living with the disease. Currently, JAK inhibitors represent the only approved class of therapies specifically used to treat myelofibrosis, highlighting the need for additional therapeutic approaches. Selinexor is an oral, first-in-class XPO1 inhibitor that selectively blocks the nuclear export protein XPO1, potentially restoring the activity of important tumour-suppressing proteins within cells. Beyond the myelofibrosis programme, XPOVIO is already approved in the United States for certain adults with relapsed or refractory multiple myeloma. Karyopharm is also investigating selinexor across other hematological cancer indications. The company has disclosed that it entered a restructuring support agreement and filed for Chapter 11 bankruptcy protection in November 2026, with a proposed transaction expected to close in the first quarter of 2027, subject to applicable conditions. Overall, the FDA acceptance of the selinexor and ruxolitinib sNDA represents an important milestone in myelofibrosis drug development, with the upcoming June 2027 regulatory decision expected to determine whether this investigational combination can become a new treatment option for eligible patients.
Source: Karyopharm Therapeutics press release



